ACP3 and prostate carcinoma: Although not well defined, the generation of a strong, persistent antigen-specific humoral and T-cell immune response by activated antigen-presenting cells is the proposed mechanism of action, which targets prostatic acid phosphatase, a highly expressed antigen in most prostate cancer cells [3,4].